Eurosurveillance banner




Announcements
Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Weekly Release  2004: Volume 8/ Issue 24 Article 3 Printer friendly version
Back to Table of Contents
Previous Next

Eurosurveillance, Volume 8, Issue 24, 10 June 2004
Articles

Citation style for this article: Kelly C. Tonsil study provides estimate of the number of people in the UK who could be incubating vCJD. Euro Surveill. 2004;8(24):pii=2485. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2485

Tonsil study provides estimate of the number of people in the UK who could be incubating vCJD

Carole Kelly (carole.kelly@hpa.org.uk), Health Protection Agency Communicable Disease Surveillance Centre, London, England

A study providing an estimate of the number of individuals in the United Kingdom (UK) who may be incubating variant Creutzfeldt-Jakob disease (vCJD), has recently been published [1]. A distinctive feature of this disease is the distribution of abnormal prion protein in the peripheral lymphatic system, particularly in tonsil tissue, which may be detected during the preclinical phase [2,3].

Researchers used immunohistochemistry to test for the presence of abnormal prion protein in 12 674 appendix and tonsil samples, which were collected from histopathology departments across the UK and anonymised prior to testing. Three of the samples showed evidence of the abnormal prion protein associated with vCJD. An extrapolation of these findings provides an estimate that approximately 3800 individuals within the UK population could be incubating this disease.

After consideration of these results and the advice of a scientific committee of the Medical Research Council (http://www.mrc.ac.uk/) and the Department of Health for England (http://www.doh.gov.uk), the Health Protection Agency (http://www.hpa.org.uk) was commissioned to undertake a much larger study, which involves establishing a national prospective archive of tonsil tissue for studies of detectable abnormal prion protein - the National Anonymous Tonsil Archive (NATA) [4]. Leftover tonsil tissue from 100 000 people of all ages removed during routine tonsillectomies will be collected. Once anonymised, these specimens will be tested for the presence of the abnormal prion protein that causes vCJD, and the results of this study should provide more precise estimates of the number of people with asymptomatic vCJD infection. These refined estimates will enable further interventions to limit the impact of vCJD and care provision for those who may develop the disease to be planned.

References:
  1. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Richie D, Penney M, Hegazy D, Ironside JW. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004: Epub 21 May 2004.DOI 10.1002/path.1580. (abstract available at http://www3.interscience.wiley.com/cgi-bin/abstract/108563520/ABSTRACT) [accessed 10 June 2004]
  2. Horby P. The prevalence of abnormal prion protein in the United Kingdom: new data and plans for a tonsil archive. Eurosurveillance Weekly 2002; 6(39): 26/09/2002 .(http://www.eurosurveillance.org/ew/2002/020926.asp#4)
  3. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Penney M, Ritchie D, Ironside JW. Accumulation of prion protein in tonsil and appendix: review of tissue samples. BMJ 2002; 325: 633-4. (http://bmj.com/cgi/reprint/325/7365/633.pdf)
  4. HPA. The National Anonymous Tonsil Archive: a resource for Creuzfeld-Jakob disease studies. Commun Dis Rep CDR Wkly 2003; 13(44): news. (http://www.hpa.org.uk/cdr/PDFfiles/2003/cdr4403.pdf)

back to top



Back to Table of Contents
Previous Next

Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.